Press Release —
Hikma Pharmaceuticals PLC announced an
exclusive licensing agreement with Adalvo to commercialize a nasal spray
medication used to treat an increasingly prevalent respiratory disease,
allergic rhinitis (AR), Hikma said in a statement.
اضافة اعلان
The exclusive
licensing and supply agreement with Adalvo expands Hikma’s respiratory
portfolio in the MENA region.
The licensed
product is a combination treatment in a single advanced delivery system that
has proven efficacy and safety in treating patients with AR. The medication
will help more patients control their symptoms, with an advantage of a faster
onset of action and fewer adverse effects.
The agreement
covers key
MENA markets, the statement said.
“Our latest
agreement with Adalvo aligns with Hikma’s strategy of creating a
well-diversified pipeline of high-value products, while further solidifying our
commercial presence in MENA,” Mazen Darwazah, Hikma’s executive vice chairman
and president of MENA.
“By partnering
with a dynamic and progressive company like Adalvo, we are building on our
ongoing commitment to offering patients access to high-quality respiratory
medications that actively support their treatment journey towards better
health,” Darwazeh added.
Adalvo CEO Anil
Okay said: “We are thrilled to be partnering with Hikma, a well-established
multinational company having a track record of creating high-quality medicines
and making them accessible to the people who need them.”
“This collaboration further accelerates our growth
at an international level, and underlines our capabilities of bringing
differentiated, high value products to the market, whilst also expanding our
allergy and respiratory pipeline,” Okay added.
Read more Business
Jordan News
.jpg)
.jpg)
